William Blair analyst Ryan Sundby downgrades Six Flags Entertainment (NYSE:SIX) from Outperform to Market Perform.
Roche Walks Away From HOOKIPA Pharma-Partnered KRAS-Focused Cancer Deal
HOOKIPA Pharma's strategic focus on HB-200 program for HPV16+ HNSCC, infectious disease cure collaboration with Gilead, and recent developments.